Roche Breast Cancer Drug Appears to Greatly Extend Patients’ Lives

Perjeta, approved by the F.D.A. in 2012, prolonged median survival time about 16 months in a trial of 808 people with metastatic breast cancer.

Source: NYT Health - September 28, 2014 Category: Consumer Health News Authors: By ANDREW POLLACK Tags: Clinical Trials Perjeta Drugs (Pharmaceuticals) Roche Holding AG Genentech Inc Herceptin (Drug) Breast Cancer HER2 Source Type: news